Bristol-Myers Squibb (BMY) – Research Analysts’ Weekly Ratings Changes

A number of research firms have changed their ratings and price targets for Bristol-Myers Squibb (NYSE: BMY):

  • 7/28/2022 – Bristol-Myers Squibb had its price target raised by analysts at Atlantic Securities from $82.00 to $83.00. They now have an “overweight” rating on the stock.
  • 7/28/2022 – Bristol-Myers Squibb had its “maintains” rating reaffirmed by analysts at UBS Group AG.
  • 7/28/2022 – Bristol-Myers Squibb had its “maintains” rating reaffirmed by analysts at Morgan Stanley. They now have a $61.00 price target on the stock, down previously from $63.00.
  • 7/28/2022 – Bristol-Myers Squibb had its price target raised by analysts at JPMorgan Chase & Co. from $80.00 to $85.00.
  • 7/27/2022 – Bristol-Myers Squibb had its price target raised by analysts at UBS Group AG to $73.00. They now have an “outperform” rating on the stock.
  • 6/6/2022 – Bristol-Myers Squibb had its price target raised by analysts at Bank of America Co. from $78.00 to $80.00. They now have a “buy” rating on the stock.

Bristol-Myers Squibb Trading Down 0.4 %

Shares of NYSE BMY opened at $72.99 on Thursday. Bristol-Myers Squibb has a 1-year low of $53.22 and a 1-year high of $80.59. The company has a market cap of $155.85 billion, a PE ratio of 24.25, a P/E/G ratio of 1.56 and a beta of 0.40. The company has a current ratio of 1.44, a quick ratio of 1.34 and a debt-to-equity ratio of 1.14. The company has a 50-day moving average of $75.19 and a two-hundred day moving average of $72.69.

Bristol-Myers Squibb (NYSE:BMYGet Rating) last announced its earnings results on Wednesday, July 27th. The biopharmaceutical company reported $1.93 earnings per share for the quarter, topping analysts’ consensus estimates of $1.79 by $0.14. Bristol-Myers Squibb had a net margin of 14.04% and a return on equity of 49.31%. The company had revenue of $11.89 billion during the quarter, compared to the consensus estimate of $11.50 billion. During the same period in the previous year, the firm posted $1.93 earnings per share. The company’s revenue was up 1.6% on a year-over-year basis. As a group, equities analysts expect that Bristol-Myers Squibb will post 7.53 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 1st. Shareholders of record on Friday, July 1st were paid a $0.54 dividend. This represents a $2.16 dividend on an annualized basis and a dividend yield of 2.96%. The ex-dividend date was Thursday, June 30th. Bristol-Myers Squibb’s dividend payout ratio is presently 71.76%.

Insider Transactions at Bristol-Myers Squibb

In other news, CEO Giovanni Caforio sold 30,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, June 13th. The shares were sold at an average price of $74.04, for a total transaction of $2,221,200.00. Following the completion of the sale, the chief executive officer now owns 551,104 shares in the company, valued at approximately $40,803,740.16. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, EVP Sandra Leung sold 65,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $74.89, for a total transaction of $4,867,850.00. Following the completion of the sale, the executive vice president now owns 308,627 shares in the company, valued at approximately $23,113,076.03. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Giovanni Caforio sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, June 13th. The shares were sold at an average price of $74.04, for a total transaction of $2,221,200.00. Following the transaction, the chief executive officer now owns 551,104 shares of the company’s stock, valued at approximately $40,803,740.16. The disclosure for this sale can be found here. 0.09% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Wilbanks Smith & Thomas Asset Management LLC grew its holdings in Bristol-Myers Squibb by 0.4% during the second quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 167,526 shares of the biopharmaceutical company’s stock valued at $12,900,000 after purchasing an additional 635 shares during the period. Thoroughbred Financial Services LLC grew its holdings in Bristol-Myers Squibb by 34.8% during the second quarter. Thoroughbred Financial Services LLC now owns 13,496 shares of the biopharmaceutical company’s stock valued at $1,039,000 after purchasing an additional 3,483 shares during the period. Hazlett Burt & Watson Inc. grew its holdings in Bristol-Myers Squibb by 3.2% during the second quarter. Hazlett Burt & Watson Inc. now owns 8,154 shares of the biopharmaceutical company’s stock valued at $626,000 after purchasing an additional 251 shares during the period. Envestnet Asset Management Inc. lifted its stake in Bristol-Myers Squibb by 1.8% in the second quarter. Envestnet Asset Management Inc. now owns 2,515,484 shares of the biopharmaceutical company’s stock valued at $193,692,000 after buying an additional 45,388 shares in the last quarter. Finally, Unigestion Holding SA lifted its stake in Bristol-Myers Squibb by 21.0% in the second quarter. Unigestion Holding SA now owns 232,926 shares of the biopharmaceutical company’s stock valued at $17,936,000 after buying an additional 40,432 shares in the last quarter. Institutional investors and hedge funds own 73.07% of the company’s stock.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.

See Also

Want More Great Investing Ideas?

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.